Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy in patients with nicotine stomatitis.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a controlled clinical trial.

This study aimed to treat smoker's palate (SP) using 5-aminolevulinic acid (5-ALA)-mediated photodynamic therapy (PDT).

Who Took Part

According to the abstract, 24 patients were involved.

A total of 24 patients with SP were divided into two groups: group-I (test group; n = 12); and group-II (control group; n = 12).

Group-I patients were treated with 5-ALA-mediated PDT, while group-II patients were advised to cease the smoking habit during the entire duration of the study and later.

How the Study Was Run

PDT was repeated on days 3, 7, and 14 (i.e., a total of four sittings including day 0 [baseline]).

Later, the participants were called for follow-up after week-4 (1st follow-up), week-6 (2nd follow-up), and week-8 (3rd follow-up) after the completion of the treatment.

The SPSS version 22.0 was used for data analysis.

What Was Measured

The subject headings attached to it are Aminolevulinic Acid, Leukoplakia, Oral, Nicotine, Photochemotherapy, Photosensitizing Agents and Stomatitis.

The authors tagged it with the keywords Photodynamic therapy, Smoker's palate and Smoking.

What This Means in Plain Language

This is a controlled clinical trial of Therapeutic nicotine (patch, non-peptide) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Photodiagnosis and photodynamic therapy), a journal based in Netherlands.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.